Stoke Therapeutics
stoketherapeutics.com
Actively hiring
Rare Disease Therapeutics
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
Stoke Therapeutics recently announced that it will present first-in-human translational data for its investigational ADOA therapy STK-002 at the AAO 2026 meeting, while continuing dose escalation in the Phase 1 OSPREY trial across eight active European si
Read more
Report
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Compugen (CGEN)
Tipranks Press Release.
Read more
Report
Stoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual Meeting
Read more
Report
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass., October 05, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in d
Read more
Report
Stoke Therapeutics stock heads into November 3 results below key averages
Stoke Therapeutics stock was last at USD 25.62 on October 2, 2026, 17.8 percent below its 200-day average. Q2 revenue beat estimates, but GAAP EPS missed.
Read more
Report
Stoke Therapeutics appoints new independent board director
Detailed price information for Stoke Therapeutics Inc (STOK-Q) from The Globe and Mail including charting and trades.
Read more
Report
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.
Read more
Report
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Stoke Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
43/100
Developer tools
Microsoft Excel
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$206k
Typical range
$80k – $345k
Open positions
10
10
Jobs
Junior
10%
Senior
50%
Architect
40%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 1 | $80k | $80k |
| Senior | 5 | $196k | $110k – $308k |
| Architect | 4 | $301k | $199k – $345k |
Highest paying role
Vice President, Strategic Sourcing & Procurement
$345k
Normalized to USD per year
All salaries at Stoke Therapeutics
By role, level and city, against the market · 10 jobs with pay
People
Barry Ticho
Executive Officer
Charles Allerson
Executive Officer
Gene Liau
Executive Officer
Adrian Krainer
Executive Officer, Director
Edward Kaye
Executive Officer, Director
Meena Meena
Executive Officer
Isabel Aznarez
Executive Officer
Huw Nash
Executive Officer
Seth Harrison
Director
Samuel Hall
Director
Arthur Levin
Director
Arthur Tzianabos
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
38/100
Slowing
Open positions
10
2 opened / 0 closed in 30 days
ATS activity
Every ~3 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Public Policy
33% ▲
Operations
22% ▼
Science & Research
22% ▲
Legal
11% ▲
Field & Service
11% ▲
Actively hiring for Public Policy (+3 in 30 days)
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Bedford
Bedford
United States
HQ
Bedford
10 open roles 9 posted in 90 days 20% engineering 50-200 est. staff $223k Avg Salary
hires for Public Policy, Operations, Science & Research
45 Wiggins Ave, Bedford, MA 01730
Financials
Total raised
$90M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2018 | $90M | Details |